论文部分内容阅读
目的观察不同剂量阿托伐他汀对2型糖尿病合并血脂异常患者的临床疗效。方法将97例2型糖尿病合并血脂异常的患者随机分成A组31例,B组34例,C组32例,在常规降血糖的同时,每晚口服阿托伐他汀片A组10mg,B组20mg,C组40mg,观察口服药物后8周,患者TC、TG、HDL-C、LDL-C、hs-CRP的变化。结果治疗8周后B组、C组TC、TG、LDL-C水平明显低于A组(P<0.05),B组C组HDL-C较A组明显上升(P<0.05),hs-CRP水平B组、C组较A组显著下降(P<0.01)。B组和C组之间差异无统计学意义,但C组较A组B组副作用大。结论 20mg阿托伐他汀片不仅能改善2型糖尿病合并血脂异常患者的血脂,还可以降低血浆hs-CRP水平,具有抗炎稳定斑块的作用。
Objective To observe the clinical effects of different doses of atorvastatin on type 2 diabetic patients with dyslipidemia. Methods A total of 97 patients with type 2 diabetes mellitus and dyslipidemia were randomly divided into group A (n = 31), group B (n = 34) and group C (n = 32). Group B received atorvastatin A 20mg, C group 40mg, observe the changes of TC, TG, HDL-C, LDL-C, hs-CRP in patients after oral administration for 8 weeks. Results After 8 weeks of treatment, the levels of TC, TG and LDL-C in group B and C were significantly lower than those in group A (P <0.05). HDL-C in group C was significantly higher than that in group A (P <0.05) The level of B group, C group than the A group decreased significantly (P <0.01). There was no significant difference between group B and group C, but group C had more side effects than group B. Conclusion 20mg atorvastatin tablet can not only improve the blood lipid of patients with type 2 diabetes and dyslipidemia, but also reduce the level of hs-CRP in plasma with anti-inflammatory and stable plaque.